☆ 4.7 Meeting Abstract

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

BLOOD (2016)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.59.59

Keywords

-

Categories

Hematology

Funding

  1. Seattle Genetics
  2. BMS
  3. Abbvie
  4. ADC Therapeutics
  5. Genentech
  6. Incyte
  7. Celgene
  8. Pfizer
  9. Infinity
  10. Pharmacyclics
  11. ARIAD
  12. Novartis
  13. Teva
  14. Pharmacyclics, LLC, an AbbVie Company
  15. Gilead
  16. Acerta

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.